CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-Myc Axis

被引:1
作者
Tang, Yongchang [1 ,2 ]
Yuan, Feng [1 ,3 ]
Cao, Mingbo [1 ]
Ren, Yupeng [1 ]
Li, Yuxuan [1 ]
Yang, Gaoyuan [1 ]
Zhong, Zhaozhong [1 ,4 ]
Liang, Hao [5 ]
Xiong, Zhiyong [5 ]
He, Zhiwei [1 ]
Lin, Nan [1 ]
Deng, Meihai [1 ]
Yao, Zhicheng [5 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Guangzhou 510630, Peoples R China
[2] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan 250012, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou 510120, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Kidney Transplantat, Guangzhou 510630, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary & Pancreat Surg, Guangzhou 510630, Peoples R China
关键词
c-Myc; circRNA; hepatocellular carcinoma; Lenvatinib resistance; PSIP1; MEDIATES SORAFENIB RESISTANCE; CANCER STEM-CELLS; CIRCULAR RNAS; THERAPY;
D O I
10.1002/advs.202410591
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Circular RNAs (circRNAs) are crucial regulators of targeted drug resistance in hepatocellular carcinoma (HCC). However, the specific mechanisms underlying resistance that significantly hampers the effectiveness of HCC treatments remain unclear. Here, it is found that circRNA-mTOR is highly expressed in HCC and strongly correlated with patient prognosis. Furthermore, circRNA-mTOR enhances the stemness of HCC cells, thereby promoting the progression of HCC and contributing to lenvatinib resistance. Mechanistically, circRNA-mTOR promotes the nuclear translocation of the RNA-binding protein (RBP) PC4 and SRSF1 interacting protein 1 (PSIP1) through specific binding. The enhancement of HCC cell stemness by circRNA-mTOR occurs via the PSIP1/c-Myc signaling pathway, ultimately driving HCC progression and lenvatinib resistance. This study highlights the important role of circRNA-mTOR in HCC progression and the maintenance of lenvatinib resistance and underscores its potential as a biomarker for the diagnosis and prognosis of HCC. In conclusion, this study provides an experimental foundation for targeted drug therapy in HCC and offers novel insights, perspectives, and methodologies for understanding the development and occurrence of this disease. These findings are significant for the development of new diagnostic and therapeutic markers for HCC, with the ultimate goal of reducing drug resistance.
引用
收藏
页数:14
相关论文
共 45 条
[1]   Lenvatinib: A Review in Hepatocellular Carcinoma [J].
Al-Salama, Zaina T. ;
Syed, Yahiya Y. ;
Scott, Lesley J. .
DRUGS, 2019, 79 (06) :665-674
[2]   circRNA Biogenesis Competes with Pre-mRNA Splicing [J].
Ashwal-Fluss, Reut ;
Meyer, Markus ;
Pamudurti, Nagarjuna Reddy ;
Ivanov, Andranik ;
Bartok, Osnat ;
Hanan, Mor ;
Evantal, Naveh ;
Memczak, Sebastian ;
Rajewsky, Nikolaus ;
Kadener, Sebastian .
MOLECULAR CELL, 2014, 56 (01) :55-66
[3]   The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway [J].
Chen, Jianxiang ;
Rajasekaran, Muthukumar ;
Xia, Hongping ;
Zhang, Xiaoqian ;
Kong, Shik Nie ;
Sekar, Karthik ;
Seshachalam, Veerabrahma Pratap ;
Deivasigamani, Amudha ;
Goh, Brian Kim Poh ;
Ooi, London Lucien ;
Hong, Wanjin ;
Hui, Kam M. .
GUT, 2016, 65 (09) :1522-1534
[4]   Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma [J].
Chen, Yunhao ;
Ling, Zhenan ;
Cai, Xianlei ;
Xu, Yongfang ;
Lv, Zhen ;
Da Man ;
Ge, Jiangzhen ;
Yu, Chengkuan ;
Zhang, Deguo ;
Zhang, Yanpeng ;
Xie, Haiyang ;
Zhou, Lin ;
Wu, Jian ;
Zheng, Shusen .
CANCER RESEARCH, 2022, 82 (04) :599-614
[5]   Identification of RNA binding protein interacting with circular RNA and hub candidate network for hepatocellular carcinoma [J].
Cheng, Binglin ;
Tian, Jingdong ;
Chen, Yuhan .
AGING-US, 2021, 13 (12) :16124-16143
[6]   The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production [J].
Dong, Wei ;
Dai, Zhi-hui ;
Liu, Fu-Chen ;
Guo, Xing-gang ;
Ge, Chun-mei ;
Ding, Jin ;
Liu, Hui ;
Yang, Fu .
EBIOMEDICINE, 2019, 45 :155-167
[7]   Identifying and Characterizing circRNA-Protein Interaction [J].
Du, William W. ;
Zhang, Chao ;
Yang, Weining ;
Yong, Tianqiao ;
Awan, Faryal Mehwish ;
Yang, Burton B. .
THERANOSTICS, 2017, 7 (17) :4183-4191
[8]   Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer [J].
French, Juliet D. ;
Johnatty, Sharon E. ;
Lu, Yi ;
Beesley, Jonathan ;
Gao, Bo ;
Kalimutho, Murugan ;
Henderson, Michelle J. ;
Russell, Amanda J. ;
Kar, Siddhartha ;
Chen, Xiaoqing ;
Hillman, Kristine M. ;
Kaufmann, Susanne ;
Sivakumaran, Haran ;
O'Reilly, Martin ;
Wang, Chen ;
Korbie, Darren J. ;
Lambrechts, Diether ;
Despierre, Evelyn ;
Van Nieuwenhuysen, Els ;
Lambrechts, Sandrina ;
Vergote, Ignace ;
Karlan, Beth ;
Lester, Jenny ;
Orsulic, Sandra ;
Walsh, Christine ;
Fasching, Peter A. ;
Beckmann, Matthias W. ;
Ekici, Arif B. ;
Hein, Alexander ;
Matsuo, Keitaro ;
Hosono, Satoyo ;
Pisterer, Jacobus ;
Hillemanns, Peter ;
Nakanishi, Toru ;
Yatabe, Yasushi ;
Goodman, Marc T. ;
Lurie, Galina ;
Matsuno, Rayna K. ;
Thompson, Pamela J. ;
Pejovic, Tanja ;
Bean, Yukie ;
Heitz, Florian ;
Harter, Philipp ;
du Bois, Andreas ;
Schwaab, Ira ;
Hogdall, Estrid ;
Kjaer, Susanne K. ;
Jensen, Allan ;
Hogdall, Claus ;
Lundvall, Lene .
ONCOTARGET, 2016, 7 (06) :6353-6368
[9]   Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling [J].
Gu, Yang ;
Wang, Yanying ;
He, Luyun ;
Zhang, Jiahang ;
Zhu, Xiaoxiao ;
Liu, Nian ;
Wang, Jianyi ;
Lu, Tiankun ;
He, Lei ;
Tian, Yong ;
Fan, Zusen .
MOLECULAR CANCER, 2021, 20 (01)
[10]   Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations [J].
Guarnerio, Jlenia ;
Bezzi, Marco ;
Jeong, Jong Cheol ;
Paffenholz, Stella V. ;
Berry, Kelsey ;
Naldini, Matteo M. ;
Lo-Coco, Francesco ;
Tay, Yvonne ;
Beck, Andrew H. ;
Pandolfi, Pier Paolo .
CELL, 2016, 165 (02) :289-302